Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GlaxoSmithKline UK and US Performance Share Plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan notifications. The only financial data points present are the share prices used for notional re-investment on January 8, 2013:
- Ordinary Share price: 1363.50 pence
- American Depositary Share (ADS) price: $43.98
Material Changes
The filing details increases in notional interests in Ordinary Shares and ADSs for specific individuals following the notional re-investment of dividends paid on January 3, 2013. There is no comparative financial data or discussion of material changes to the company's operational or financial status versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Key Facts for Investor Verification
- Transaction Type: Notification of notional interest increases in Performance Share Plans due to dividend re-investment.
- Participants: Dr. M M Slaoui (connected person: Dr. K Slaoui) and Mr. P C Thomson (connected person: Mrs. K Thomson).
- Share Counts: Dr. K Slaoui received 22.521 ADSs; Mr. P C Thomson received 56.689 Ordinary Shares.
- Pricing: Transactions were calculated at 1363.50 pence per Ordinary Share and $43.98 per ADS.
- Regulatory Basis: Filed in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).